Pharmaceuticals
JW Therapeutics Announces Receipt of Breakthrough Therapy Designation for Carteyva® in Mantle Cell Lymphoma in China
SHANGHAI, April 3, 2022 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an independent, innovative biotechnology company focused on developing, manufacturing and commercializing cell immunotherapy products, announced that the Center for Drug Evaluation (CDE) of the National Medical Products Admini...
2022-04-03 18:05
5268
Dada's JDDJ in action to guarantee medical supply and online health consultation with pharmaceutical partners
SHANGHAI, April 2, 2022 /PRNewswire/ -- As a number of cities in China are ramping up anti-epidemic measures, more consumers rely on online-to-offline services to purchase much-needed medications. JDDJ, one ofChina's largest local on-demand retail platforms operated by Dada Group (Nasdaq: DADA), ...
2022-04-02 20:53
4052
Peijia Medical Announces 2021 Annual Results
Dual Engines Promote Commercialization Total Revenue Increased by 253.2% HONG KONG, April 2, 2022 /PRNewswire/ -- Peijia Medical Limited ("Peijia Medical" or the "Company", together with its subsidiaries, the "Group", stock code: 9996), a leading player in the high-growth transcatheter valve th...
2022-04-02 00:06
11248
Pharming Announces Positive Data from Phase II/III Leniolisib Trial Presented at Clinical Immunology Society 2022 Annual Meeting
LEIDEN, Netherlands, April 1, 2022 /PRNewswire/ -- Pharming Group N.V. ("Pharming" or "the Company") (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces new data from the pivotal Phase II/III trial of leniolisib for the treatment of activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS)...
2022-04-01 23:45
7122
Zhongze Therapeutics Announces Successful Completion Of The First-In-Human Dose Escalation Study of ZZ6398 in Healthy Volunteers
SHANGHAI, April 1, 2022 /PRNewswire/ -- Zhongze Therapeutics, a clinical stage biotech company focused on the discovery, development and commercialization of innovative and transformative therapies for both psychiatric and neurological disorders announced today the successful completion of the fi...
2022-04-01 16:55
2052
Akeso Reported 2021 Annual Results
Penpulimab Started Commercialization and Cadonilimab Filed for NDA HONG KONG, April 1, 2022 /PRNewswire/ -- Akeso, Inc. (9926.HK) ( "Akeso" ), a China-based biopharmaceutical company focusing on the development and commercialization of innovative therapeutic antibodies for Oncology & Immunology,...
2022-04-01 13:44
25565
Zhimeng Biopharma Announces Dosing of First Subject in First-in-Human Phase -- Clinical Trial of CB06
SHANGHAI, March 31, 2022 /PRNewswire/ -- Shanghai Zhimeng Biopharma, Inc. ("Zhimeng"), an innovation-driven biopharmaceutical company focused on the development of innovative drugs for the treatment of chronic hepatitis B and central nervous system diseases, announced dosing of the first particip...
2022-03-31 23:40
2159
Aceemzyme Co., Ltd., challenging to new drug of brain diseases with recombinase-based ginsenoside Rh2 (s) mass production technology…
- Under development of ginsenoside Rh2(s) mass production technology… - "Enhanced production of ginsenoside Rh2(S) from PPD-type major ginsenosides using BglSk cloned fromSaccharibacillus kuerlensis together with two glycosidase in series" SOUTH KOREA, Seoul, March 31, 2022 /PRNewswire/ -- Ginse...
2022-03-31 21:00
1373
I-Mab Announces Voluntary Lock-ups by Key Shareholders and Senior Management for Long-Term Commitment
SHANGHAI and GAITHERSBURG, Md., March 31, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that the Company's key shareholders including CBC Grou...
2022-03-31 20:00
1906
Brii Bio Presents New Data on BRII-835 (VIR-2218) in Chinese Patients with Chronic Hepatitis B at APASL 2022
New data demonstrate BRII-835 (VIR-2218) was well tolerated with notable
reductions in serum HBsAgobserved in the Chinese patients infected with chronic
hepatitis B
DURHAM, N.C. and BEIJING, March 31, 2022 /PRNewswire/ -- Brii Biosciences
2022-03-31 18:05
4219
Novavax Submits Request to Expand Conditional Marketing Authorization of COVID-19 Vaccine in the European Union to Adolescents (Ages 12-17)
* If granted, Nuvaxovid™ COVID-19 Vaccine (recombinant, adjuvanted) would be the first protein-based option for adolescents aged 12-17 years inEurope GAITHERSBURG, Md., March 31, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializi...
2022-03-31 18:00
4428
Airway Therapeutics Announces First Patient Dosed in Phase 1b Trial of AT-100 in Preterm Infants at Risk for Bronchopulmonary Dysplasia (BPD)
Novel preventative AT-100 offers potential to reduce incidence and severity of serious respiratory disease BPD, improving outcomes in very preterm infants MARIETTA, Ga., March 31, 2022 /PRNewswire/ -- Airway Therapeutics, Inc. (Airway), a biopharmaceutical company developing a new class of biolog...
2022-03-31 17:00
3813
JW Therapeutics Announces IND Approval for the Pivotal Clinical Trial of Carteyva® in Second-line Large B-Cell Lymphoma
SHANGHAI, March 31, 2022 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an independent, innovative biotechnology company focused on developing, manufacturing and commercializing cell immunotherapy products, announced that it has received the Investigational New Drug (IND) clearance from the Nation...
2022-03-31 12:20
4134
CStone announces first patient enrollment in the U.S. in the Phase 1 clinical trial of CS5001, a potential global best-in-class ROR1-targeting ADC
* Commencement of the first-in-human clinical trial of CS5001 marks another key milestone for CStone's Pipeline 2.0 * Global development of CS5001 is conducted in the form of a multi-regional clinical trial, with sites initiated in the US andAustralia, and an IND application accepted by the ...
2022-03-31 08:02
4405
Everest Medicines Submits New Drug Application in Hong Kong for Sacituzumab Govitecan in Second-Line Metastatic Triple-Negative Breast Cancer
SHANGHAI, March 31, 2022 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products to address critical unmet needs inAsia Pacific markets, announced today that it has submitted a New Drug Applicat...
2022-03-31 08:00
5104
LifeTech Scientific Corporation（1302.HK） Announces 2021 Annual Results
Excluding certain non-recurring items, the net profit attributable to owners of the Company increased by 76.8% to RMB 324.0million SHENZHEN, China, March 30, 2022 /PRNewswire/ -- LifeTech Scientific Corporation (LifeTech, 1302.HK), a leading company specialized in minimally invasive interventio...
2022-03-31 03:27
3997
Transcenta Announces Presentation of Preclinical Data of TST005 at the 2022 American Association for Cancer Research (AACR) Annual Meeting
SUZHOU, China, March 30, 2022 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces the preclinical data...
2022-03-30 19:28
2945
BioVaxys Expands Cancer Vaccine Platform
BVX-0922 to Target Colorectal Cancer Under Investigator-Sponsored IND VANCOUVER, BC, March 30, 2022 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV), (FRA: 5LB), (OTCQB: BVAXF) ("BioVaxys" or "Company"), announced today the expansion of its cancer vaccine platform with BVX-0922, its autolog...
2022-03-30 16:02
4536
First Year of Commercialization, Alphamab Oncology Reports Full Year 2021 Financial Results and Business Highlights
SUZHOU, China, March 30, 2022 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) reported financial results for the full year endedDecember 31, 2021 and highlighted recent progress and upcoming milestones. Highlights * First product launch: In November 2021, KN035 (Envafolimab) has receiv...
2022-03-30 10:36
2777
First Year of Commercialization, Alphamab Oncology Reports Full Year 2021 Financial Results and Business Highlights
SUZHOU, China, March 29, 2022 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) reported financial results for the full year endedDecember 31, 2021 and highlighted recent progress and upcoming milestones. Highlights * First product launch: In November 2021, KN035 (Envafolimab) has receiv...
2022-03-30 10:35
2442
Week's Top Stories
Most Reposted
Franchising & Licensing Asia 2026 Opens New Chapter Under MP, Strengthening Singapore's Position as Asia's Franchise and Licensing Hub
[Picked up by 309 media titles]
2026-07-30 10:45
J.P. Morgan Private Bank Earns Record 10 Accolades at The Asset Triple A Private Capital Awards 2026
[Picked up by 294 media titles]
2026-07-30 15:00ADA acquires Algonomy, strengthening its intelligent growth platform for a fully agentic experience
[Picked up by 290 media titles]
2026-07-30 15:30
MetaOptics and Elsoft partner to scale next-generation semiconductor optics manufacturing equipment
[Picked up by 286 media titles]
2026-07-30 18:15Most Read
Franchising & Licensing Asia 2026 Opens New Chapter Under MP, Strengthening Singapore's Position as Asia's Franchise and Licensing Hub
2026-07-30 10:45
14998
